Lab Briefs

Share on facebook
Share on twitter
Share on linkedin
Share on print
Share on email

University of Miami Settles Lab Qui Tam Lawsuit for $22 Million

EARLIER THIS MONTH, THE FEDERAL DEPARTMENT OF JUSTICE (DOJ) announced a settlement with the University of Miami that resolves allegations that the university ordered medically-unnecessary tests and submitted false claims to federal healthcare programs. 

In the settlement, the University of Miami will pay $22 million to resolve the claims and will enter into a five-year corporate integrity agreement with the Department of Health and Human Services. 

Different whistleblowers filed three different qui tam lawsuits in 2013 and 2014 alleging similar violations of federal law. One case was filed by Jonathan Lord, MD, who was Chief Operating Officer at UHealth, the university’s health system. A second qui tam action was filed by Philip Chen, MD, and Joshua Yellen, who were Vice Chair of Pathology and Vice Chairman for Administration, Dept. of Pathology, respectively at the University of Miami. The third qui tam case was filed by Mitchell Watson, now a former finance director for Jackson Memorial Hospital.

PathAI Generates $165 Million in New Funding from Investors

DIGITAL PATHOLOGY GOT ANOTHER MAJOR VOTE OF INVESTOR CONFIDENCE after Boston-based PathAI announced that its Series C funding round raised $165 million. 

Some of the notable companies investing in this funding round were Kaiser Permanente, Bristol-Myers Squibb, Labcorp, and Merck Global Health Innovation Fund.

PathAI describes itself as a “provider of artificial intelligence-powered technology for pathology. The company said it will “deploy its new capital to accelerate product development while continuing to prioritize the improvement of patient outcomes with reliable AI-powered technology and meaningful collaboration with pharmaceutical and diagnostic partners.”

FierceBiotech described PathAI’s platform as using “machine learning and deep learning to improve both diagnostic and treatment capabilities by identifying disease biomarkers and predicting how individual patients will respond to various treatments.” 

One sign of PathAI’s progress on developing algorithms to analyze digital pathology images is the collaboration it has with Labcorp, which expanded its existing relationship with PathAI earlier this year. FierceBiotech said that “the exended partnership will see Labcorp use PathAI’s algorithms to identify disease-specific biomarkers and the biomarker-positive patients who will respond best to certain treatments to improve clinical trials managed by Labcorp’s drug development arm.”

November Return of  Executive War College

ALL SIGNS ARE AUSPICIOUS THAT THE PANDEMIC in the United States has eased and restrictions on air travel and live conferences are lifting in state after state. Based on this, The Dark Report is working with a hotel to produce a smaller-sized Executive War College on Lab and Pathology Management. 

The likely site will be San Antonio and will happen in the first week of November, 2021. Our office hears regularly from lab professionals ready to attend this event and eager for the opportunity to network with peers and lab vendors while learning about new trends and developments in the lab and pathology marketplace. 

Comments

;

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

Privacy Policy: We will never share your personal information.